Daniel-Paul Bednarík, Ph.D. Email and Phone Number
Daniel-Paul Bednarík, Ph.D. work email
- Valid
- Valid
Daniel-Paul Bednarík, Ph.D. personal email
- Valid
- Valid
- Valid
Daniel-Paul Bednarík, Ph.D. phone numbers
DANIEL BEDNARIK - CORE COMPETENCIES:- Leads molecular designs for new cellular adoptive and nanoparticle-based immunotherapy- CAR-T cellular design and construction/molecular engineering- Expert in exosome-based therapeutic and diagnostic designs- Expert in cardiovascular genomics and translational research- 30 years experience with viral infectious diseases- Experienced with Dept. of Defense/BARDA/DARPA funding processes – Recipient of $1.7M Phase-I DARPA contract- Bioinformatics, genomics, database development- Stratification of clinical trials using human biomarkers- Animal model development for cardiovascular disease- Experienced with FDA Advisory Committees- Experienced in writing/submitting regulatory agency documents- Biotech Startups -- Raising private equity from private and state sources- Extensive consulting experience in Pharma and BiotechDaniel Bednarik, PhD is currently Senior Vice President, Molecular Engineering & Protein Design. Dan was previously Vice President, Molecular Engineering Unit, at Intrexon Corporation. He led a team of 23 staff members focused upon the company's synthetic biology needs and piloted their first CAR-T program (UltraCart). He was previously co-founder and Vice President of Cardiovascular Biology of Artesian Therapeutics, Inc., which was acquired by Cardiome Pharma (Vancouver, BC) in 2005. He created the largest known cardiovascular gene expression database for Gene Logic and has published key translational research for heart disease. Dr. Bednarik served as a key scientist in the development of Human Genome Sciences (HGS) database and has 30 years of experience in the field of virology with emphasis on HIV and herpes virus pathology. He was co-recipient of a $2MM DARPA contract in 2006 where he and his colleagues developed a novel non-host method for rapid vaccine manufacture. Dan also is experienced in developing and managing clinical programs. His training in Biochemistry was completed at Temple University School of Medicine (Philadelphia) in 1985, and The Johns Hopkins University Oncology Center (Baltimore).
-
Principal ConsultantMelitus BiotechHighland, Md, Us
-
Chief Technology OfficerBlack Canyon Bio Jun 2024 - PresentCurrently assisting with the financing and technology development for the new company in a contract consulting position.
-
ConsultantMirecule, Inc. May 2024 - PresentGaithersburg, M.D, UsI am serving as a molecular and protein design consultant. -
Principal ConsultantThe Bioforge Group, Llc Jan 2024 - Present -
Advisor And CollaboratorUniversity Of Pennsylvania Mar 2024 - PresentPhiladelphia, Pa, UsFocused on the translational biology of heart function and disease states. -
Board MemberResonance Dx Jan 2019 - Feb 2024
-
ConsultantAcidophil Llc Mar 2017 - Feb 2024 -
Senior Vice President (Former), Molecular Engineering & Protein DesignNeximmune, Inc. Feb 2016 - Feb 2024NexImmune, is an early stage biopharmaceutical company, grounds its novel technology on the discoveries from the laboratory of Drs. Jonathan Schneck and Mathias Oelke of The Johns Hopkins University, both Scientific Co-founders of NexImmune, that reports the development of a new approach for adoptive cellular therapy. In this study artificial Antigen Presenting Cells (aAPC) were used to stimulate rapid ex-vivo Enrichment and Expansion (E+E) of tumor-specific T cells. Within a two-week period, these cancer fighting cells were expanded to numbers that represent potentially therapeutic levels – when they could be adoptively transfused back into a patient in the form of cellular immunotherapy. This new technology can also be used to validate patient-specific neoantigens. Neoantigens are formed as a result of mutations arising in cancer cells and can be detected by a patient’s T cells with the same strength as they may detect microbial antigens. Neoantigens have recently been described as clinically desirable targets for the development of personalized cancer immunotherapies.
-
Executive ConsultantNeximmune, Inc. Jun 2015 - Feb 2017NexImmune, an early stage biopharmaceutical company, grounds its novel technology on the discoveries from the laboratory of Dr. Jonathan Schneck of The Johns Hopkins University, a Scientific Co-founder of NexImmune, that reports the development of a new approach for adoptive cellular therapy. In this study artificial Antigen Presenting Cells (aAPC) were used to stimulate rapid ex-vivo Enrichment and Expansion (E+E) of tumor-specific T cells. Within a two-week period, these cancer fighting cells were expanded to numbers that represent potentially therapeutic levels – when they could be adoptively transfused back into a patient in the form of cellular immunotherapy. This new technology can also be used to validate patient-specific neoantigens. Neoantigens are formed as a result of mutations arising in cancer cells and can be detected by a patient’s T cells with the same strength as they may detect microbial antigens. Neoantigens have recently been described as clinically desirable targets for the development of personalized cancer immunotherapies.
-
Executive Consultant, OperationsMicrobion Corporation Jul 2015 - Jun 2017Bozeman, Montana, UsMicrobion’s bismuth-thiol (BT) family of compounds have potent, broad spectrum efficacy against all antibiotic resistant bacteria tested to date. Additionally they have the highly advantageous and product-differentiating capability to prevent and eradicate microbial biofilms. Their effectiveness against MRSA, MDR TB, CRE, VRE, and other antibiotic resistant pathogens highlights their potential to provide solutions to the dramatic and alarming increase in global antibiotic resistance. -
ConsultantBioit Solutions Mar 2012 - Jun 2017Silver Spring, Md, UsBioIT is a Silver Spring Maryland-based software company specializing in Biotechnology applications, providing a novel line of Portal Products. The founders of BioIT originated from Human Genome Sciences, Inc. (HGS) where the CIO, Michael Fannon, served as the primary architect and designer of that company's cutting edge bioinformatic database and genomics tools. My role with BioIT is to help extend product development and bring this unique capability to clients in the biotechnology and pharmaceutical industry on a customized basis. My experience with bioinformatics and genomics provides BioIT with new potential user bases and development of new functionality. -
ConsultantAntidote Therapeutics, Inc. Aug 2016 - Feb 2017Development of stable cell lines for company's RCB and MCB. Expression of nicotine monoclonal antibodies that facilitate smoking cessation.
-
Vice President, Molecular Engineering Unit (Meu) OperationsIntrexon Corporation Aug 2013 - Apr 2015Germantown, Maryland, UsPromoted to Vice President in August, 2013 #Daniel Bednarik -- Oversees the operations of the company's Molecular Engineering Unit and synthetic biology programs, with emphasis on new gene switch designs and their translation to immuno-oncology and adoptive T-cell therapies (CAR-T). Works closely with the Health Sector Division head and Senior Management and is a member of the Executive Committee led by Randal J. Kirk (Chairman & CEO). The MEU employs Intrexon's proprietary technologies that grounds the company's commercial efforts for synthetic biology approaches to treat cancer, and other diseases. The MEU serves as a central nexus to support all corporate divisions programs. Addresses molecular technology needs to foster partnerships, new business development opportunities, and ensures MEU processes are optimized to maintain seamless operation for both company and external partners. See http://www.dna.com/OurApproach/Process/CoreTechnologyUnits for the current MEU mission. -
Senior Director, Molecular Engineering Unit (Meu) OperationsIntrexon Corporation Aug 2012 - Aug 2013Germantown, Maryland, UsOversees the company's Molecular Engineering Unit and program. Works closely with the COO, CSO, President of the Human Therapeutics Division (HTD), Senior Director of Translational Research, Business Development, and Cell Engineering Unit (CEU). The MEU employs Intrexon's proprietary "Ultravector Technology" that grounds the company's commercial efforts for gene therapy, multigenic gene program expression, and synthetic biology for treatment of cancer, and other diseases. The MEU is a pivotal facilitator of Translational Medicine/Research for Intrexon. Addresses molecular technology needs to foster partnerships, new business development opportunities, and ensures MEU processes are optimized to maintain seamless operation for both company and external partners. Dr. Bednarik and his team speialize in therapeutic miRNA solutions. www.dna.com
-
Director, Genomics & Bioinformatics; Head, Infectious Diseases ProgramCardiome Pharma Corporation Nov 2007 - Sep 2012I was acquired by Cardiome initially as a consultant to transition the Artesian assets into the company for two years, then hired by the company. I worked for Cardiome in total for 7 years. Cardiome is a research-based biopharmaceutical company dedicated to the discovery, development and commercialization of new therapies that will improve the quality of life and health of patients. We strive to find innovative medicines that provide value to patients, physicians and healthcare systems. While working for Cardiome, I have focused efforts on development of new biomarker-driven efforts to simplify clinical trial stratification.I conceived and launched the Cardiome Antiviral Discovery program - This program couples the discovery and development of "first in class" antiviral small molecules to target a unique ion channel called the "Viroporins". Cardiome's strength in ion channel biology is expected to put a new face on the therapeutic targeting of these proteins. This program received funding through a grant awarded by the Canadian Institutes of Health Research (CIHR) - $500,000 (CAD) per year for 3 years.
-
ConsultantCardiome Pharma Corporation Oct 2005 - Nov 2007Post-acquisition responsibilities included transition of CRPM and BRPM programs into Cardiome Pharma Corp., acting as Program Manager and designing new animal studies for therapeutic compound validation.
-
Director, Advisory BoardAblitech, Inc. 2012 - 2012The company's lead siRNA and antisense DNA delivery product, Versadel, is undergoing pre-clinical testing with the intention of partnering with major pharmas. My role for Ablitech is to establish and organize the Scientific Advisory Board (SAB) and assist in the critique of ongoing scientific projects.
-
Consultant & AdvisorIndel Therapeutics Inc. Mar 2009 - 2012Indel Therapeutics Inc. is a biopharmaceutical company dedicated to developing new drugs to address the global health crisis caused by antibiotic resistance. The Company has a growing pipeline of novel antibiotic drug discovery programs that focus on curing difficult-to-treat and hospital-acquired infections. These programs are based on Indel’s paradigm-changing antimicrobial drug discovery platform, a patented technology that has opened a rich, new area of drug targets for the treatment of bacterial and parasitic infections and, potentially, fungal and viral infections.My role for Indel Therapeutics has been to identify new opportunities, assist in the company's interface with the US Dept. of Defense, and provide insights and advice regarding bioinformatics, database development, and recruitment of funding.See - www.indelrx.com
-
Scientific Advisor - Nx Pharmagen, Inc.Nx Pharmagen, Inc. 2009 - 2012NX PharmaGen’s groundbreaking technologies are paving the way for patients to realize the promise of personalized medicine in cancer and other diseases. The company employs a novel approach to predictive molecular diagnostics by profiling a unique class of biological messengers called "exosomes" or "microvesicles". My role has been to support the scientific aspects of product development as well as the bioinformatic needs and objectives of the company.See - www.nxpharmagen.com
-
Director, Business DevelopmentExonhit Therapeutics Oct 2009 - Sep 2010Paris, FrDirected new business development efforts, partnering, and translation of corporate technology to practice in the business sector. Worked directly with Vice President, Business Development and Vice President of R&D to execute database partnering opportunities. -
ConsultantBradmer Pharmaceuticals, Inc. Oct 2008 - Jan 2009Consulting for drug development.
-
Vp & Cofounder - Cardiovascular BiologyArtesian Therapeutics, Inc. 2002 - 2005Served as co-founder of company spin out from Gene Logic, Inc. in 2002. Quickly defined relationships between dysregulation of gene expression and small molecule SAR. The program led to two therapeutic classes of molecules designed to restore ejection of blood to the failing heart while suppressing beta-agonist pathways. This led to a rapid exit via sale of the company to Cardiome Pharma Corp. in October, 2005.
-
Director, Cardiovascular Database DevelopmentGene Logic Aug 1997 - Jun 2002Gaithersburg, Md, UsDr. Bednarik created the largest known cardiovascular gene expression database for Gene Logic, which served as a prized source of cardiovascular disease data for multiple pharma companies, and grounded the basis for founding Artesian Therapeutics. This database integrated unique personal and clinical biosample attributes with changes in gene expression in disease-vs-normal cardiovascular tissues derived from man and animal model systems. Along with other disease programs at Gene Logic, it propelled a revolution in disease pathway and drug discovery. -
Director, Scientific AffairsAdvanced Bioresearch Associates Aug 1997 - Sep 1998Pre-clinical study development and reporting for the medical device and pharmaceutical industry.
-
ScientistHuman Genome Sciences 1993 - 1997Served as molecular biologist and bioinformatics scientist - Discovery, characterization, and patenting of novel genes for development of therapeutic proteins.
Daniel-Paul Bednarík, Ph.D. Skills
Daniel-Paul Bednarík, Ph.D. Education Details
-
Temple University - Lewis Katz School Of MedicineBiochemistry -
The Johns Hopkins UniversityOncology And Cancer Biology/Virology
-
Rider UniversityBiology
-
Somerville High SchoolHigh School Diploma
Frequently Asked Questions about Daniel-Paul Bednarík, Ph.D.
What company does Daniel-Paul Bednarík, Ph.D. work for?
Daniel-Paul Bednarík, Ph.D. works for Melitus Biotech
What is Daniel-Paul Bednarík, Ph.D.'s role at the current company?
Daniel-Paul Bednarík, Ph.D.'s current role is Principal Consultant.
What is Daniel-Paul Bednarík, Ph.D.'s email address?
Daniel-Paul Bednarík, Ph.D.'s email address is te****@****aol.com
What is Daniel-Paul Bednarík, Ph.D.'s direct phone number?
Daniel-Paul Bednarík, Ph.D.'s direct phone number is +144386*****
What schools did Daniel-Paul Bednarík, Ph.D. attend?
Daniel-Paul Bednarík, Ph.D. attended Temple University - Lewis Katz School Of Medicine, The Johns Hopkins University, Rider University, Somerville High School.
What are some of Daniel-Paul Bednarík, Ph.D.'s interests?
Daniel-Paul Bednarík, Ph.D. has interest in Horses, Home Improvement, Reading, Gourmet Cooking, Sports, Fishing, Home Decoration, Health, Children, Cooking.
What skills is Daniel-Paul Bednarík, Ph.D. known for?
Daniel-Paul Bednarík, Ph.D. has skills like Biotechnology, Drug Discovery, Molecular Biology, Drug Development, Genomics, Pharmaceutical Industry, Clinical Development, Infectious Diseases, Bioinformatics, Oncology, Cancer, Clinical Trials.
Free Chrome Extension
Find emails, phones & company data instantly
Aero Online
Your AI prospecting assistant
Select data to include:
0 records × $0.02 per record
Download 750 million emails and 100 million phone numbers
Access emails and phone numbers of over 750 million business users. Instantly download verified profiles using 20+ filters, including location, job title, company, function, and industry.
Start your free trial